NEW YORK (GenomeWeb News) — Canadian biomarker company Miraculins has withdrawn its offer to acquire diagnostics developer IBEX technologies.
In mid-November Winnipeg-based Miraculins made an unsolicited offer to acquire IBEX through a stock deal that would exchange one common Miraculins share for five shares in IBEX.